UBS Bumps FY12 EPS Estimate on IDEX Corp (IEX); Preview of Q2

July 6, 2012 12:28 PM EDT Send to a Friend
Get Alerts IEX Hot Sheet
Price: $56.44 +1.11%

Rating Summary:
    5 Buy, 8 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 11 | Down: 35 | New: 23
Trade IEX Now!
UBS maintains a 'Neutral' on IDEX Corp (NYSE: IEX) price target of $43.00 (from $46.00).

Analyst, Robert Barry, on Q2: Expect an in line 2Q after raising our estimate by $0.01: We think the Health & Science (HST) segment benefited from higher pharma capex and less India end market weakness, two factors that weighed on 1Q.

On FY12: 2012E EPS rises $0.02 to $2.84 on an improved outlook for HST revenue and margins, net of added Europe/China-related conservatism in FMT and FSD. We’re also nudging up the FX headwind we see this year.

Overall view of stock: 2012 look achievable, but concerns in NIH funding may come to the forefront and weigh on post-2012 growth prospects. Also lower liquidity may limit upside.

For an analyst ratings summary and ratings history on IDEX Corp click here. For more ratings news on IDEX Corp click here.

Shares of IDEX Corp closed at $39.77 yesterday, with a 52 week range of $29.29-$47.28.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here



You May Also Be Interested In


Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment